Oral contraceptive tablets containing 20 and 30 μg of ethinyl estradiol with 150 μg desogestrel: Their influence on lipids, lipoproteins, sex hormone binding globulin and testosterone

References

• Jick H, Dinan B, Rothman K J. Oral contraceptives and non-fatal myocardial infarction. JAMA 1978; 239: 1403–6
   PubMed Web of Science ®Google Scholar
• Stadel B V. Oral contraceptives and cardiovascular disease. New Eng J Med 1981; 305: 612–8
   PubMed Web of Science ®Google Scholar
• Meades E W, Haines A P, North W RS, Chakrabarti R, Howarth D I, Stirling Y. Haemostatic. lipid and blood pressure profiles of women on oral contraceptives containing 50 mikrogram and 30 mikrogram estrogen. Lancet 1977; ii: 948–51
   Google Scholar
• Böttiger L E, Boman G, Eklund G, Westerholm B. Oral contraceptives and thromboembolic disease: effect of lowering estrogen content. Lancet 1980; i: 1097–101
   Google Scholar
• Thorogood M, Mann J, Murphy M, Vessey M. Is oral contraceptive use still associated with an increased risk of fatal myocardial infarction? Report of a case-control study. Br J Obstet Gynaecol 1991; 98: 1245–53
   PubMedGoogle Scholar
• Stampfer M J, Willett W C, Colditz G A, Speizer F E, Hennekens C H. Past use of oral contraceptives and cardiovascular disease: a meta-analysis in the context of the Nurses' Health Study. Am J Obstet Gynecol 1990; 163: 285–91
   Google Scholar
• Bounds W, Vessey M, Wiggins P. A randomized double blind trial of two low-dose combined oral contraceptives. Br J Obstet Gynaecol 1979; 86: 325–9
   Google Scholar
• Bergink E W, Borglin N E, Klottrup P, Liukko P. Effect of desogestrel and levonorgestrel in low-dose estrogen oral contraceptives on serum lipoproteins. Contraception 1982; 25: 477–85
   Google Scholar
• Fotherby K. Oral contraceptives, lipids and cardiovascular disease. Contraception 1985; 31: 367–94
   PubMed Web of Science ®Google Scholar
• Cullberg G. Pharmacodynamic studies on desogestrel administered alone and in combination with ethinylestradiol. (Thesis) Acta Obstet Gynecol Scand Suppl 1985; 133: 1–28
   Google Scholar
• Lammers P, op ten Berg M. Phase III clinical trial with a new oral contraceptive containing 150 ug desorgestrel and 20 μg ethinylestradiol. Acta Obstet Gynecol Scand 1991; 70: 497–500
   PubMed Web of Science ®Google Scholar
• Kloosterboer H J, van Wayen R GA, van der Ende A. Effects of the oral contraceptive combination 0.150 mg desogestrel+0.020 mg ethinylestradiol on serum lipids including the HDL subfractions. Acta Obstet Gynecol Scand Suppl 1987; 144: 33–6
   Google Scholar
• Tuimala R, Korhonen M, Kortesluoma M. Effects of the oral contraceptive combination 0.150 mg desogestrel + 0.020 mg etinylestradiol on serum lipids, SHBG, glycosylated proteins and plasma antithrombin III activity in healthy women. Acta Obstet Gynecol Scand Suppl 1987; 144: 37–9
   Google Scholar
• Goldstein J L, Brown M S. The low-density lipoprotein pathway and its relation to atherosclerosis. Ann Rev Biochem 1977; 46: 897–930
   PubMed Web of Science ®Google Scholar
• Finley P R, Schifman R B, Williams R J, Lichti D A. Cholesterol in high density lipoprotein: use of Mg2+/dextran sulfate in its enzymatic measurement. Clin Chem 1978; 24: 931–3
   PubMed Web of Science ®Google Scholar
• Demacker P N, van Sommeren-Zondag D F, Stalenhoef A F, Stuyt P M, van't Laar A. Ultracentrifugation in swingingbucket and fixed-angle rotors evaluated for isolation and determination of high-density lipoprotein subfractions HDL2 and HDL3. Clin Chem 1983; 29: 656–63
   Google Scholar
• Becker W, Rapp W, Schwick H G, St. Oriko K. Methoden zur quantitativen Bestimmung von Plasmaproteinen durch Immunopräzipitation. Clin Chem Biochem 1968; 6: 113–22
   Google Scholar
• Takayama M, Itoh S, Nakasaki T, Tanimizu I. A new enzymatic method for determination of serum choline-con-taining phospholipids. Clin Chem Acta 1977; 79: 93–8
   PubMed Web of Science ®Google Scholar
• Jacobs N J, van Demark J. The purification and properties of alfa-glycerophosphatase-oxidating enzyme of Streptococcus faecalis 10Cl. Arch Biochem Biophys 1960; 88: 250–5
   Google Scholar
• Niemi S, Mäentusta O, Bolton N J, Hammond H L. Time resolved immunofluorometric assay of sex-hormone binding globulin. Clin Chem 1988; 34: 63–6
   Google Scholar
• Levell M J, Siddall J K, Rowe E, Glashan R W, Robinson M R, Pidcock N B. Relationship of testosterone, sex hormone binding globulin, and calculated free testosterone to subsequent clinical progress in patients with carcinoma of the prostate treated with bilateral orchidectomy or estrogens. The Prostate 1987; 11: 17–21
   Google Scholar
• Bradley J W. Distribution-free statistical tests. Prentice-Hall, LondonEngland 1968; 68–86
   Google Scholar
• Song S, Jun-Kang C, Pei-Juan Y, et al. A cross-over study of three oral contraceptives containing ethinyloestradiol and either desogestrel or levonorgestrel. Contraception 1992; 45: 523–32
   PubMed Web of Science ®Google Scholar
• Kannel W B, Castelli W P, Gordon T, McNamara P M. Serum cholesterol, lipoproteins, and risk of coronary heart disease: the Framingham Study. Ann Intern Med 1971; 74: 1–12
   PubMed Web of Science ®Google Scholar
• Kannel W B. Metabolic risk factors for coronary heart disease in women: perspective from the Framingham Study. Am Heart J 1987; 114: 413–9
   PubMed Web of Science ®Google Scholar
• Godsland I F, Crook D, Simpson R, et al. The effects of different formulations of contraceptive agents on lipid and carbohydrate metabolism. New Engl J Med 1990; 323: 1375–81
   PubMed Web of Science ®Google Scholar
• Miccoli R, Orlandi M C, Fruzzetti F, et al. Metabolic effects of three new low-dose pills: a six-months' experience. Contraception 1989; 39: 643–52
   Google Scholar
• Gevers Leuven J A, Drijkoningen G JA, Alers J, Havekes L, Dersjant Roorda M. The effect of low dose oral contraceptives on lipoprotein lipid and apolipoprotein levels in smoking and non-smoking women. J Drug Ther Res 1988; 13: 355–9
   Google Scholar
• Prasad R NV, Liew D, Ratnam S S. Comparative metabolic effects of three types of combined oral contraceptive pills in Chinese women. Contraception 1989; 39: 21–35
   PubMed Web of Science ®Google Scholar
• Levy D, Kannel W B. Cardiovascular risks: new insights from Framingham. Am Heart J 1988; 116: 266–72
   PubMed Web of Science ®Google Scholar
• Jacobs D R, Jr, Mebane I L, Bangdiwala S I, Criqui M H, Tyroler H A. High density lipoprotein cholesterol as a predictor of cardiovascular disease mortality in men and women: the follow-up study of the Lipid Research Clinics Prevalence Study. Am J Epidemiol 1990; 131: 32–47
   PubMed Web of Science ®Google Scholar
• Godsland I F, Wynn V, Crook D, Miller N E. Sex, plasma lipoproteins, and atherosclerosis: prevailing assumptions and outstanding questions. Am Heart J 1987; 114: 1467–503
   PubMed Web of Science ®Google Scholar
• Lipson A, Stoy D B, LaRosa J C, et al. Progestins and oral contraceptive-induced lipoprotein changes: a prospective study. Contraception 1986; 34: 121–34
   PubMed Web of Science ®Google Scholar
• Miller N E. Associations of high-density lipoproteins subclasses and apolipoproteins with ischemic heart disease and coronary atherosclerosis. Am Heart J 1987; 113: 589–97
   PubMed Web of Science ®Google Scholar
• Adams M R, Clarkson T B, Koritnik D R, Nash H A. Contraceptive steroids and coronary artery atherosclerosis in cynomololgus macaques. Fertil Steril 1987; 47: 1010–7
   PubMed Web of Science ®Google Scholar
• Schaefer E J, Foster D M, Zech L A, Lindgren F T, Bruer H B, Jr, Levy R I. The effects of estrogen administration on plasma lipoprotein metabolism in premenopausal females. J Clin Endocrinol Metab 1983; 57: 262–7
   PubMed Web of Science ®Google Scholar
• Van der Vange N, Kloosterboer H J, Haspels A A. Effects of seven low dose combined oral contraceptives on high density lipoprotein subfractions. Br J Obstet Gynaecol 1987; 94: 559–67
   Google Scholar
• Arvins A L, Haber R J, Fulley S B. The status of hypertriglyceridemia as a risk factor for coronary heart disease. Clin Lab Med 1989; 9: 153–68
   Google Scholar
• Bilotta P, Fuvilli S. Clinical evaluation of a monophasic ethinylestradiol/desogestrel-containing oral contraceptive. Arzneimitt Forch. 1988; 38: 932–4
   PubMed Web of Science ®Google Scholar
• Cullberg G, Dovré P A, Lindstedt G, Steffensen K. On the use of plasma proteins as indicators of the metabolic effects of combined oral contraceptives. Acta Obstet Gynecol Scand 1982; 111: 47–54
   Google Scholar